Jeffrey Snyder, MD
Urology · Littleton, CONPI 1386737328
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 61.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $4,169 and has fallen 93.2% since, to $282 in 2024.
Across 59 payments — averaging $147.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$5K
- Teleflex LLC$1K
- Boston Scientific$395
- Covidien LP$335
- Progenics Pharmaceuticals, Inc.$239
- Neotract Inc.$229
- plus $1K from 15 others
Across 18 payments — averaging $3849.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$48K
- Astellas Pharma Global Development$22K
What the payments were for
- Consulting fees$3354%
- Speaking & faculty fees$5,14559%
- Travel & lodging$2773%
- Food & beverage$2,81832%
- Education$1111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $5,362 |
| Teleflex LLC | 9 | $1,039 |
| Boston Scientific | 7 | $395 |
| Covidien LP | 1 | $335 |
| Progenics Pharmaceuticals, Inc. | 3 | $239 |
| Neotract Inc. | 3 | $229 |
| AbbVie(2 entities) | 5 | $210 |
| Procept Biorobotics Corporation | 1 | $167 |
| Dendreon Pharmaceuticals LLC | 4 | $131 |
| Palette Life Sciences, Inc. | 1 | $126 |
| Bayer | 1 | $124 |
| Astellas Pharma Global Development | 1 | $93 |
| Johnson & Johnson | 3 | $56 |
| Olympus America Inc. | 2 | $30 |
| 180 Medical, Inc. | 2 | $30 |
| Myriad Genetic Laboratories, Inc. | 2 | $29 |
| Amgen | 1 | $24 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$5,145
- UroLift$724
- GENERAL - THERAPIES$243
- PYLARIFY$220
- AquaBeam Robotic System$167
- UroLift System$152
- BOTOX$149
- Xofigo$124
- GENERAL ERECTILE DYSFUNCTION$105
How this compares
$8,685 in reported general payments places this provider in the 75th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 17 | $15,414 |
| MyrbetriqMirabegron | 21 | $14,715 |
| Trospium Chloride ErTrospium Chloride | 13 | $2,385 |
| Tamsulosin Hcl | 214 | $2,071 |
| Methenamine Hippurate | 31 | $1,773 |
| Finasteride | 107 | $739 |
| Imipramine Hcl | 28 | $713 |
| Oxybutynin Chloride ErOxybutynin Chloride | 47 | $661 |
| Solifenacin Succinate | 14 | $517 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $227 |
| Ciprofloxacin Hcl | 12 | $87 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $5,362 | $14,71521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 225 urology providers in Colorado.
Other urology in Littleton
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
- Nicholas WestfallGrand Junction$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.